Reaction
Hypogeusia reporting signals
As of the last recalculation, Hypogeusia appears in 1,935 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is VISMODEGIB (PRR 59.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vismodegib | 48 | 59.5 | 59.8 |
| Sunitinib Malate | 60 | 16.9 | 16.9 |
| Selinexor | 12 | 15.0 | 15.0 |
| Avapritinib | 15 | 13.4 | 13.4 |
| Quinine | 7 | 8.8 | 8.8 |
| Rizatriptan Benzoate | 8 | 8.5 | 8.5 |
| Regorafenib | 9 | 8.4 | 8.4 |
| Prochlorperazine Maleate | 7 | 8.2 | 8.2 |
| Cabozantinib | 34 | 7.7 | 7.7 |
| Nintedanib | 22 | 7.6 | 7.6 |
| Terazosin Hydrochloride | 6 | 7.3 | 7.3 |
| Prochlorperazine | 18 | 7.0 | 7.0 |
| Pazopanib Hydrochloride | 16 | 6.4 | 6.4 |
| Granisetron | 6 | 6.2 | 6.2 |
| Pirfenidone | 23 | 6.1 | 6.1 |
| Enzalutamide | 28 | 5.2 | 5.2 |
| Ixazomib | 12 | 4.5 | 4.5 |
| Erlotinib | 4 | 4.4 | 4.5 |
| Axitinib | 8 | 4.4 | 4.4 |
| Erlotinib Hydrochloride | 5 | 4.3 | 4.3 |
| Crizotinib | 5 | 4.2 | 4.2 |
| Bendamustine Hydrochloride | 4 | 3.6 | 3.6 |
| Lenalidomide | 132 | 3.5 | 3.5 |
| Palbociclib | 29 | 3.3 | 3.3 |
| Encorafenib | 3 | 3.3 | 3.3 |
| Apalutamide | 3 | 2.7 | 2.7 |
| Nirmatrelvir And Ritonavir | 13 | 2.6 | 2.6 |
| Lifitegrast | 3 | 2.0 | 2.0 |
| Dupilumab | 67 | 1.5 | 1.5 |